CCBIO Seminar – Hege F. Berg
Hege F. Berg from the University of Bergen will give a talk entitled “Endometrial cancer model systems to improve treatment.” This work was recently published in Communications Medicine.
Speaker: Hege Fredriksen Berg
Hege is a PhD candidate in her last year in the Krakstad group, in the research field Preclinical models for endometrial cancer. She has established a collection of patient-derived endometrial cancer organoids and organoid-based xenograft models.
Organoid models have proven to be highly useful in cancer research and models have been established from several cancer types. This seminar present the group's recent work to establish genetically stable models from all types of endometrial cancer. The work was recently published in Communications Medicine (https://rdcu.be/cqT0a).
Title: “Endometrial cancer model systems to improve treatment”
Time: 14.30, Thursday August 26.
Where: Digital seminar, in a Zoom webinar. Link: https://uib.zoom.us/j/61399295455?pwd=a3BHR2VBQUxjOFdLckRZbHpyL3I2UT09
Is asked for a passcode, use: 9ZEzecdq
Host: Harsh Dongre
Endometrial cancer is the most common malignancy of the female reproductive system in countries with high developmental index. Standard treatment for endometrial cancer is surgery, with adjuvant chemotherapy given for high risk or advanced disease. Still, 15-20% of patients experience recurrence. Alternative treatment options for this patient group are few and targeted drugs have not yet reached the clinic for endometrial cancer patients. To bridge the gap between bench and clinic, more advanced cellular models are emerging, such as 3D tumor organoids that mimic the molecular features of the matched patient tissue. Multiple co-clinical trials have demonstrated similar drug responses between patients and their corresponding organoid model, implying a great potential of organoids in translational research. Cancer modeling and the establishment of a new preclinical platform for endometrial cancer will be discussed. This includes the establishment of patient-derived endometrial cancer organoids and organoid-based xenograft models. The models are profiled at DNA, RNA and protein levels, and molecular features mimic the corresponding patient tissue. The clinical relevance of these models is further evaluated by treatment with conventional chemotherapy and are currently used in testing of targeted therapies.
Note: Please change any username to your name when logging in, so that chair can address you by name if you have questions.
- Your sound and video will be turned off as default for security reasons, and only host can de-mute individual participants.
- We will open for questions after the lecture, where you can use the Raise hand function, or type your question in Chat. Host will then de-mute your sound and address you by your name (please log on with your name).
- If you think you might want to ask questions, please test your microphone beforehand. Make sure your microphone is turned on. (Or ask host to read out your typed question).
- We advise all to have a Zoom account on your device beforehand (free service), that will save you some minutes when logging on.
Those of us with University of Bergen (UiB) client machines, might already have Zoom. If not, see https://it.uib.no/Jeg_skal_bruke_Zoom_for_f%C3%B8rste_gang
For private machines (not UiB), see https://zoom.us/download#client_4meeting Otherwise, clicking the logon link provided above will prompt the Zoom app to download, but it saves you time to have done this beforehand.